Reed it and weep haters. Our company grew 5.7% last year. Not too shabby when you consider every other pharma company is losing money year after year. Things are looking damn good at Takeda, if you don't believe me then read below. There are no layoffs, no doom and gloom. Sorry haters.
Takeda posts rise in full-year profit, sales, as emerging markets, new products offset Actos decline
(Ref: Takeda, NASDAQ, MarketWatch, PR Newswire)
May 9th, 2013
By: Matthew Dennis
Tags: Corporate Affairs Takeda Actos Azilva Blopress Daxas Dexilant Leuplin Nesina Prevacid Reminyl Takepron Uloric Velcade
Takeda announced Thursday that net income for the 12 months ended March 31 reached 131.2 billion yen ($1.3 billion), up 5.7 percent on the prior year, boosted by a one-time tax refund of 57.4 billion yen ($581 million) and sales growth in emerging markets. However, the figure fell below analyst estimates of 165.8 billion yen ($1.7 billion) and the company predicted a drop in net income and sales for the current year below its earlier expectations.
For fiscal 2013, the drugmaker said it now forecasts a 28 percent drop in net income to 95 billion yen ($962 million), with sales of 1.59 trillion yen ($16.1 billion), below a previous estimate of 1.63 trillion yen ($16.5 billion). Analysts had been predicting an outlook of 146 billion yen ($1.5 billion) in net income, with revenue of around 1.63 trillion yen. "In terms of the medical product environment in Japan and Europe, there is a clear tendency for each country to control medical costs," said Iwaaki Taniguchi, Takeda's senior vice president in charge of corporate finance. The executive also attributed its lower forecasts on delayed market penetration of Daxas, which the company gained via its acquisition of Nycomed.
Takeda noted that in fiscal 2012, overall sales grew 3.2 percent 1.6 trillion yen ($16.2 billion), with gains from new products in Japan, the US and Europe, including Nesina, Reminyl, Azilva, Dexilant and Uloric, offsetting a decrease in Actos revenue due to the entry of generic competition. Annual sales of the diabetes therapy slipped 58.5 percent versus the year earlier to 122.9 billion yen ($1.2 billion).
For other products, sales of Blopress declined 21.6 percent to 169.6 billion yen ($1.7 billion), with revenue from Leuplin falling 3.5 percent to 116.5 billion yen ($1.2 billion). Meanwhile, sales of Prevacid, which is marketed as Takepron in Japan, fell 9.7 percent to 110.2 billion yen ($1.1 billion). In addition, sales of Velcade jumped 25.4 percent to 72.9 billion yen ($738 million).
Takeda posts rise in full-year profit, sales, as emerging markets, new products offset Actos decline
(Ref: Takeda, NASDAQ, MarketWatch, PR Newswire)
May 9th, 2013
By: Matthew Dennis
Tags: Corporate Affairs Takeda Actos Azilva Blopress Daxas Dexilant Leuplin Nesina Prevacid Reminyl Takepron Uloric Velcade
Takeda announced Thursday that net income for the 12 months ended March 31 reached 131.2 billion yen ($1.3 billion), up 5.7 percent on the prior year, boosted by a one-time tax refund of 57.4 billion yen ($581 million) and sales growth in emerging markets. However, the figure fell below analyst estimates of 165.8 billion yen ($1.7 billion) and the company predicted a drop in net income and sales for the current year below its earlier expectations.
For fiscal 2013, the drugmaker said it now forecasts a 28 percent drop in net income to 95 billion yen ($962 million), with sales of 1.59 trillion yen ($16.1 billion), below a previous estimate of 1.63 trillion yen ($16.5 billion). Analysts had been predicting an outlook of 146 billion yen ($1.5 billion) in net income, with revenue of around 1.63 trillion yen. "In terms of the medical product environment in Japan and Europe, there is a clear tendency for each country to control medical costs," said Iwaaki Taniguchi, Takeda's senior vice president in charge of corporate finance. The executive also attributed its lower forecasts on delayed market penetration of Daxas, which the company gained via its acquisition of Nycomed.
Takeda noted that in fiscal 2012, overall sales grew 3.2 percent 1.6 trillion yen ($16.2 billion), with gains from new products in Japan, the US and Europe, including Nesina, Reminyl, Azilva, Dexilant and Uloric, offsetting a decrease in Actos revenue due to the entry of generic competition. Annual sales of the diabetes therapy slipped 58.5 percent versus the year earlier to 122.9 billion yen ($1.2 billion).
For other products, sales of Blopress declined 21.6 percent to 169.6 billion yen ($1.7 billion), with revenue from Leuplin falling 3.5 percent to 116.5 billion yen ($1.2 billion). Meanwhile, sales of Prevacid, which is marketed as Takepron in Japan, fell 9.7 percent to 110.2 billion yen ($1.1 billion). In addition, sales of Velcade jumped 25.4 percent to 72.9 billion yen ($738 million).